NO20002409L - FremgangsmÕte for Õ produsere arsen trioksyd formuleringer og metoder for Õ behandle cancer ved Õ bruke arsen trioksyd eller melarsoprol - Google Patents

FremgangsmÕte for Õ produsere arsen trioksyd formuleringer og metoder for Õ behandle cancer ved Õ bruke arsen trioksyd eller melarsoprol

Info

Publication number
NO20002409L
NO20002409L NO20002409A NO20002409A NO20002409L NO 20002409 L NO20002409 L NO 20002409L NO 20002409 A NO20002409 A NO 20002409A NO 20002409 A NO20002409 A NO 20002409A NO 20002409 L NO20002409 L NO 20002409L
Authority
NO
Norway
Prior art keywords
arsenic trioxide
melarsoprol
procedures
methods
formulations
Prior art date
Application number
NO20002409A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002409D0 (no
Inventor
Jr Raymond P Warrell
Pier Paolo Pandolfi
Janice L Gabrilove
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22057410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20002409(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of NO20002409D0 publication Critical patent/NO20002409D0/no
Publication of NO20002409L publication Critical patent/NO20002409L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicinal Preparation (AREA)
NO20002409A 1997-11-10 2000-05-09 FremgangsmÕte for Õ produsere arsen trioksyd formuleringer og metoder for Õ behandle cancer ved Õ bruke arsen trioksyd eller melarsoprol NO20002409L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6465597P 1997-11-10 1997-11-10
PCT/US1998/024024 WO1999024029A1 (fr) 1997-11-10 1998-11-10 Procede de production de formulations a base de trioxyde d'arsenic et methodes de therapie anticancereuse utilisant du trioxyde d'arsenic ou du melarsoprol

Publications (2)

Publication Number Publication Date
NO20002409D0 NO20002409D0 (no) 2000-05-09
NO20002409L true NO20002409L (no) 2000-06-27

Family

ID=22057410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002409A NO20002409L (no) 1997-11-10 2000-05-09 FremgangsmÕte for Õ produsere arsen trioksyd formuleringer og metoder for Õ behandle cancer ved Õ bruke arsen trioksyd eller melarsoprol

Country Status (19)

Country Link
US (22) US6770304B2 (fr)
EP (3) EP2255800B1 (fr)
JP (2) JP2001522799A (fr)
KR (1) KR20010031938A (fr)
CN (1) CN1285743A (fr)
AU (1) AU747474C (fr)
BR (1) BR9814857A (fr)
CA (1) CA2309652C (fr)
CY (1) CY1113856T1 (fr)
DK (1) DK2255800T3 (fr)
ES (2) ES2395515T3 (fr)
ID (1) ID25622A (fr)
IL (1) IL136051A0 (fr)
NO (1) NO20002409L (fr)
NZ (1) NZ504585A (fr)
PL (1) PL343868A1 (fr)
PT (2) PT2255800E (fr)
TR (1) TR200002243T2 (fr)
WO (1) WO1999024029A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044559C (zh) * 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
EP1391206B1 (fr) 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant du trioxyde d'arsenic pour le traitment du lymphome non Hodgikinien
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR100272835B1 (ko) * 1998-05-08 2000-11-15 배일주 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물
KR100399657B1 (ko) 2000-06-29 2003-09-29 배일주 혈관신생 억제제
EP1309627B1 (fr) * 2000-08-08 2009-09-30 Immunomedics, Inc. Immunotherapie destinee a traiter la leucemie myelocytique chronique avec anti-nca-90 anticorps nu
CN1332672C (zh) * 2001-03-15 2007-08-22 张鹏 一种三氧化二砷注射粉剂
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
KR20030058019A (ko) * 2001-12-29 2003-07-07 한국원자력연구소 삼산화비소(Ａｓ₂Ｏ₃)를 유효 성분으로 포함하는 방사선치료증진제
JP4571408B2 (ja) 2002-01-07 2010-10-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
KR20030075017A (ko) * 2002-03-15 2003-09-22 한국원자력연구소 삼산화비소를 포함하는 혈관신생억제제
EP1356820A1 (fr) * 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccin ADN combiné avec un inducteur de l'apoptose de cellules tumorales
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
US8394422B2 (en) 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US8906422B2 (en) 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
CN100506287C (zh) * 2003-04-23 2009-07-01 台湾东洋药品工业股份有限公司 具放射性的含砷化合物的制法及其用于肿瘤治疗的用途
TWI296527B (en) 2003-04-23 2008-05-11 Inst Of Nuclear Energy Res Rocaec Radioactive aesenic-containing compounds and their uses in the treatment of tumors
GB0317020D0 (en) * 2003-07-21 2003-08-27 Sahajanand Biotech Private Ltd Herbo-mineral formulation for refractory leukemias and lymphomas
CN1304053C (zh) * 2003-08-13 2007-03-14 上海第二医科大学附属瑞金医院 一种可治愈急性早幼粒细胞白血病的组合药物
FR2860719B1 (fr) * 2003-10-10 2006-04-28 Assist Publ Hopitaux De Paris Utilisation de derives organoarsenies ou organostibiques pour leurs proprietes anticancereuses
KR100632250B1 (ko) 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm
TWI411431B (zh) 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP1721615A1 (fr) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Composition pharmaceutique comprenant de l'arsenite de sodium ou de potassium pour traiter le cancer urogenital et ses métastases
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
US20070134349A1 (en) * 2005-09-19 2007-06-14 Duke University Methods of treating hematological malignancies
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
CN101395166B (zh) 2006-01-13 2014-07-09 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
KR101009893B1 (ko) * 2007-04-06 2011-01-20 주식회사 엘지화학 고순도 헤테로폴리산의 신규한 제조방법
CN101903029B (zh) 2007-11-02 2012-09-26 Zio医药肿瘤学公司 使用有机砷化物的联合治疗
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
US8650648B2 (en) 2008-03-26 2014-02-11 Sophos Limited Method and system for detecting restricted content associated with retrieved content
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
CA2734650A1 (fr) 2008-08-20 2010-02-25 Ziopharm Oncology, Inc. Composes organoarseniques et methodes pour le traitement d'un cancer
PL2475362T3 (pl) * 2009-09-10 2019-09-30 Kominox, Inc. Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego
US8795738B2 (en) 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US9231234B2 (en) 2012-03-30 2016-01-05 Panasonic Intellectual Property Management Co., Ltd. Cylindrical battery
EP2897906B1 (fr) 2012-09-20 2017-07-05 Bendale, Yogesh Narayan Procédé de bio-synthèse de trioxyde d'arsenic nanométrique et son utilisation dans le traitement des maladies, y compris les cancers
RU2650635C2 (ru) * 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
US11077139B2 (en) 2013-12-30 2021-08-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
PL3250213T3 (pl) 2015-01-29 2023-10-30 Eupharma Pty Ltd Kompozycje zawierające arsen do stosowania w sposobach leczenia
CA2975406C (fr) * 2015-02-01 2025-07-22 Quetzal Therapeutics, Llc Compositions lyophilisees a surface specifique elevee comprenant de l'arsenic destinees a une administration orale chez des patients
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
KR102548836B1 (ko) 2016-02-25 2023-07-03 삼성디스플레이 주식회사 표시 장치
US9700580B1 (en) * 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
AU2017368444B9 (en) 2016-12-01 2020-07-02 Eupharma Pty Ltd Arsenic compositions
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
CN113491710A (zh) * 2017-02-24 2021-10-12 四川兴科蓉药业有限责任公司 β-As4S4在制备用于治疗血液系统恶性肿瘤的药物中的用途
WO2019109095A1 (fr) * 2017-12-01 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Trioxyde d'arsenic et composés d'acide rétinoïque pour le traitement de troubles associés à l'idh2
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
WO2020117868A1 (fr) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Composés d'arsenic et composés d'acide rétinoïque pour le traitement de troubles associés à l'idh
WO2020117867A1 (fr) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Darinaparsine et composés d'acide rétinoïque pour le traitement de troubles associés à l'idh
CN110101713A (zh) * 2019-05-16 2019-08-09 上海交通大学医学院附属第九人民医院 一种三氧化二砷组合物的应用
CA3138472C (fr) * 2019-05-21 2024-05-07 Medsenic Utilisation d'ions metalliques pour potentialiser les effets therapeutiques de l'arsenic
CN112675197A (zh) * 2021-01-22 2021-04-20 中山大学孙逸仙纪念医院 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
CN117137932B (zh) * 2023-10-18 2024-04-19 中国中医科学院中药研究所 一种用于肿瘤的中药复方制剂及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132275A (en) 1872-10-15 Improvement in medical compounds
US232807A (en) 1880-10-05 Herbert e
US3700498A (en) 1970-12-10 1972-10-24 Ibm Process for making electrophotographic plates
JPS5188620A (en) 1975-01-31 1976-08-03 Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho
DE3003635C2 (de) 1980-02-01 1985-07-11 Klöckner-Humboldt-Deutz AG, 5000 Köln Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien
US4501275A (en) * 1981-07-06 1985-02-26 Maahs Jerry D Mammalian subject heating unit using radiant heat
FR2539993A1 (fr) 1983-01-28 1984-08-03 Darcheux Mario Baume agissant sur les plaies cancereuses
US4950768A (en) * 1984-01-16 1990-08-21 Cronyn Marshall W Cyclic disulfonic ester cross-linking compounds
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
US4705030A (en) * 1987-02-17 1987-11-10 Tepperberg Phillip S Hand augmenting spinal manipulator encircling the hand
US4882142A (en) 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CA2011365A1 (fr) * 1989-03-06 1990-09-06 Eugene L. Inman Formule de diluant de la daptomycine
CN1061908A (zh) 1991-12-21 1992-06-17 江西省妇产医院 一种治癌药物的制造方法
CN1060935C (zh) 1992-05-31 2001-01-24 丛繁滋 用于癌病灶直接给药的砷制剂的制备方法
CN1044777C (zh) 1992-07-06 1999-08-25 杨世泽 癌痛止痛膏的配制方法
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
ES2183815T3 (es) * 1992-07-24 2003-04-01 Univ Johns Hopkins Quimioterapia para el cancer.
DE4317331A1 (de) 1993-05-25 1994-12-01 Reischle Karl Georg Behandlung von Schädigungen des Immunsystems
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
EP0804928B1 (fr) 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
CN1119113A (zh) 1994-09-22 1996-03-27 衣永德 复方癌复康胶囊及制备方法
CN1122700A (zh) 1994-11-08 1996-05-22 付知中 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法
LV11667B (en) 1995-08-14 1997-06-20 Tamara Vorobieva Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
DK1229030T3 (da) 1995-09-12 2006-02-13 Zeneus Pharma Ltd Hydrolysefremmende, hydrofobe taxanderivater
CN1058620C (zh) 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
CN1052648C (zh) 1995-12-03 2000-05-24 唐书生 癌瘤消肿止痛膏
EP1391206B1 (fr) 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant du trioxyde d'arsenic pour le traitment du lymphome non Hodgikinien
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
AU2002300339B2 (en) 1997-11-10 2006-03-02 Sloan-Kettering Institute For Cancer Research Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
AU2006202364B2 (en) 1997-11-10 2009-05-28 Sloan-Kettering Institute For Cancer Research Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法

Also Published As

Publication number Publication date
PL343868A1 (en) 2001-09-10
US20030211171A1 (en) 2003-11-13
US7879364B2 (en) 2011-02-01
US20040146571A1 (en) 2004-07-29
US20110091573A1 (en) 2011-04-21
US20040146580A1 (en) 2004-07-29
ID25622A (id) 2000-10-19
ES2395515T3 (es) 2013-02-13
EP1037625A1 (fr) 2000-09-27
PT2255800E (pt) 2012-12-17
EP1037625A4 (fr) 2002-07-31
US20030099719A1 (en) 2003-05-29
US20040146582A1 (en) 2004-07-29
IL136051A0 (en) 2001-05-20
EP2255800B1 (fr) 2012-10-17
US6770304B2 (en) 2004-08-03
US6855339B2 (en) 2005-02-15
CA2309652A1 (fr) 1999-05-20
CA2309652C (fr) 2013-01-29
CN1285743A (zh) 2001-02-28
US20040146576A1 (en) 2004-07-29
JP2010184926A (ja) 2010-08-26
US6982096B2 (en) 2006-01-03
CY1113856T1 (el) 2016-07-27
US20040146577A1 (en) 2004-07-29
EP2255800A1 (fr) 2010-12-01
PT1964557E (pt) 2013-02-20
NO20002409D0 (no) 2000-05-09
NZ504585A (en) 2002-06-28
EP1964557A1 (fr) 2008-09-03
US6884439B2 (en) 2005-04-26
DK2255800T3 (da) 2013-02-04
KR20010031938A (ko) 2001-04-16
ES2399480T3 (es) 2013-04-01
US20040146572A1 (en) 2004-07-29
TR200002243T2 (tr) 2000-12-21
US6861076B2 (en) 2005-03-01
WO1999024029A1 (fr) 1999-05-20
US20040146568A1 (en) 2004-07-29
US20040146575A1 (en) 2004-07-29
US20040146583A1 (en) 2004-07-29
US20040151782A1 (en) 2004-08-05
HK1150762A1 (en) 2012-01-13
US20040146581A1 (en) 2004-07-29
US20040146574A1 (en) 2004-07-29
US20040146578A1 (en) 2004-07-29
US20060029681A1 (en) 2006-02-09
US8273379B2 (en) 2012-09-25
US20040146570A1 (en) 2004-07-29
US6723351B2 (en) 2004-04-20
AU747474C (en) 2006-09-21
US20040146573A1 (en) 2004-07-29
BR9814857A (pt) 2001-12-26
EP1964557B1 (fr) 2013-01-02
US20040146579A1 (en) 2004-07-29
US20040146569A1 (en) 2004-07-29
AU747474B2 (en) 2002-05-16
JP2001522799A (ja) 2001-11-20
US20020013371A1 (en) 2002-01-31
AU1397399A (en) 1999-05-31

Similar Documents

Publication Publication Date Title
BR0312597A (pt) Combinações de drogas para o tratamento de neoplasmas
BR9908273A (pt) Formulações
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
FI943445A0 (fi) Vesiliukoisten teksafyriinien metallikomplekseja
CA2083179A1 (fr) Isoxazole-4-carboxamides et hydroxyalkylidenecyanoacetamides; produits pharmaceutiques a base de ces composes et leur utilisation
NO20002409D0 (no) FremgangsmÕte for Õ produsere arsenisk trioksydformuleringer og metoder for behandling av cancer ved Õ bruke arsenisk trioksyd eller melarsoprol
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
PT1203770E (pt) Piran -2-onas e 5, 6-di-hidropiran-2-onas uteis para o tratamento de hiperplasia e outras doencas
ES2118414T3 (es) Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
PT1003496E (pt) Medicamento para tratamento de neoplasia intra-epitelial prostatica
NO940266L (no) Indre strålingsskade
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DK0396184T3 (da) Anvendelse af ketoconazol og et retinoid til behandling af acne vulgaris
DK7191A (da) Topisk salve
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
HU911928D0 (en) Process for the production of chelates and its complexes containing orto ligating functional group, and the medical preparations containing thereof
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
BG101126A (en) The use of muramylpeptide compounds
ES2155519T3 (es) Preparaciones inmunoterapeuticas que contienen gamma-globulinas para tratar enfermedades cancerosas.
BR0214564A (pt) Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application